Dravet Syndrome
Symptoms, Doctors, Treatments, Advances & More

Dravet Syndrome Overview

Save information for later
Sign Up

Learn About Dravet Syndrome

What is the definition of Dravet Syndrome?
Dravet syndrome is the most severe of a group of conditions known as SCN1A-related seizure disorders. Symptoms include seizures which first occur in infancy that are often triggered by high temperatures (febrile seizures). In childhood, many types of seizures may occur and they may increase in frequency. Seizures may be difficult to treat. Other symptoms include loss of motor skills, intellectual disability, speech impairment, and difficulty with movement. Most cases of Dravet syndrome occur when the SCN1A gene is not working correctly. It can be inherited in an autosomal dominant pattern, but most people with Dravet syndrome do not have a family history of the condition. Diagnosis is based on a clinical exam, medical history, and the results of genetic testing.
What are the alternative names for Dravet Syndrome?
  • Dravet syndrome
  • Myoclonic epilepsy, severe, of infancy
  • SME
  • SMEI
  • Severe Myoclonic Epilepsy of Infancy
Who are the top Dravet Syndrome Local Doctors?
Elite in Dravet Syndrome
Elite in Dravet Syndrome
Referral may be required

Werner K Doyle M.D. PC

223 E 34th St, 
New York, NY 
212-263-8870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Orrin Devinsky is a Neurologist practicing medicine in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Dravet Syndrome. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.

Elite in Dravet Syndrome
Elite in Dravet Syndrome
Referral may be required

U Of M Neurology Clinic

1500 E Medical Center Dr, 
Ann Arbor, MI 
734-936-9020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jack Parent is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Parent is rated as an Elite provider by MediFind in the treatment of Dravet Syndrome. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome. Dr. Parent is board certified in Neurology and Clinical Neurophysiology. Dr. Parent is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Dravet Syndrome
Distinguished in Dravet Syndrome
Referral required

Atrium Health Neurology Specialty Care

1225 Harding Place, Suite 4200, 
Charlotte, NC 
704-468-0101
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajdeep Singh is a Neurologist practicing medicine in Charlotte, North Carolina. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Dravet Syndrome. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Seizures, Memory Loss, Dravet Syndrome, and Epilepsy. Dr. Singh is board certified in American Board Of Psychiatry And Neurology. Dr. Singh is currently accepting new patients.

View All Doctors
What are the latest Dravet Syndrome Clinical Trials?
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Other
Study Phase: Phase 3

Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center